Dr. Dutcus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Eisai Inc
200 Metro Boulevard
Nutley, NJ 07110Phone+1 201-699-6709Fax+1 732-791-1188- Is this information wrong?
Summary
- Senior Vice President Clinical Development
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1996 - 1999
Iuliu Hatieganu University of Medicine and PharmacyClass of 1990
Certifications & Licensure
NJ State Medical License 2002 - 2025
NY State Medical License 1999 - 2012- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsPembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Random...Yang, J., Han, B., De La Mora Jiménez, E., Lee, J., Koralewski, P., Karadurmus, N., Sugawara, S., Livi, L., Basappa, N., Quantin, X., Dudnik, J., Ortiz, D., Mekhail, T...> ;Journal of Thoracic Oncology. 2023 Dec 29
- 14 citationsLenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.Josep M Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek-Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz...> ;The Lancet. Oncology. 2023 Dec 1
- 11 citationsA Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.Vicky Makker, Carol Aghajanian, Allen L Cohn, Margarita Romeo, Raquel Bratos, Marcia S Brose, Mark Messing, Lea Dutta, Corina E Dutcus, Jie Huang, Emmett V Schmidt, Ro...> ;Journal of Clinical Oncology. 2023 Feb 10
- Join now to see all
Journal Articles
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
Press Mentions
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) in Certain Patients with Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)April 7th, 2023- Merck and Eisai Present Results from Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) Versus LENVIMA Monotherapy in Patients with Unresectable Hepatocellular CarcinomaSeptember 10th, 2022
- Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) Versus LENVIMA Monotherapy in Patients with Unresectable Hepatocellular CarcinomaAugust 3rd, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
